U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07521137) titled 'Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence' on April 02.
Brief Summary: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Candidiasis, Vulvovaginal
Intervention:
DRUG: OCF001 Intravaginal Gel
OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.
DRUG: Placebo Gel
Placebo (Gel formulation without OCF)
Recruitment Status: ...